A Phase 3 clinical trial (NCT06047548) investigating tirzepatide (LY3298176) for the maintenance of body weight reduction in participants with obesity or overweight completed its primary phase on 2026-01-20. This milestone indicates that data collection for the study's main objectives has concluded.
Background
Tirzepatide, also known by its aliases Zepbound and Mounjaro, is being evaluated for its role in long-term weight management. This specific study aimed to assess the efficacy and safety of tirzepatide for maintaining body weight reduction in individuals who have obesity or are overweight with weight-related comorbidities.
Trial design
The study, identified as NCT06047548, was a Phase 3 trial that enrolled 441 participants. It investigated tirzepatide (LY3298176) in participants diagnosed with obesity or who were overweight. The interventions included both tirzepatide and placebo arms to evaluate the drug's effect on maintaining body weight reduction.
What this means
The primary completion of this Phase 3 trial for tirzepatide signifies a critical step in its development for weight management. Data from this study will now undergo analysis to determine the drug's effectiveness and safety profile in maintaining weight reduction, which is a key challenge in the long-term treatment of obesity and overweight conditions. The findings will be important for understanding tirzepatide's potential role in sustained weight loss.
Source
Information regarding the primary completion of this clinical trial was obtained from the ClinicalTrials.gov public database. The study record for NCT06047548, titled "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-R," was updated on 2026-01-20 on clinicaltrials.gov.